INTRODUCTION
Current understanding suggests that, when environmental or signaling cues are conducive, the first APC subset to acquire Ag can have a directing role in shaping immune response outcome (1, 2) . Although innate systems ensure that some foreign Ag are detected and targeted quickly, most Ags require a more fine-tuned trafficking pathway dependent on Ag type and anatomical location. We have previously characterized the role of Ag-presenting B cells play in triggering autoimmunity and routing specific Ags to other professional APCs (1, 3, 4) . Through the expression of unique BCRs, B cells can acquire specific Ag that is present at a low concentration to amplify Ag-specific immunity (5) (6) (7) .
In vivo studies using mice transgenic for a specific B cell receptor (anti-NP) enabled us to control B cell Ag acquisition and track subsequent Ag transfer to other professional APCs (5) . Parallel experiments with human B cell and MΦ cell lines and primary cells support this mechanism in the development of human immune or autoimmune responses (8) . We also demonstrated that the B cell requires direct contact with scavenger receptor A (SR-A) on the surface of a MΦ or DC, when presenting and transferring Ag. Moreover, SR-A-mediated trafficking between B cells and MΦs is often more efficient than conventional phagocytosis of Ag by MΦs (8) . Finally, autoimmune prone MRL mice deficient in SR-A develop lower titers of autoantibodies and less pathology relative to wild type littermates (Raycroft and Mamula, unpublished).
In addition to SR-A being implicated in Ag trafficking in SLE, it is also known to be important in ligand uptake in cardiovascular disease, cell adhesion, cell-cell interactions, phagocytosis, host defense, and cellular activation (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) . These diverse properties suggest that SR-A is not a typical, static receptor, and different environmental cues or cellular interactions likely activate diverse biologic SR-A functions. These characteristics make SR-A an attractive target for modulating important immunologic pathways relevant to the development of immune-mediated diseases.
In the present study, we sought to identify novel small molecule inhibitors (SMIs) of SR-A that may alter the biology of Ag (or auto-Ag) trafficking and subsequent immunity. We screened bioactive SMI libraries and examined candidates that significantly reduce Ag transfer from B cells to MΦs ex vivo in human cell lines and in vivo in mice. Herein, we report novel SR-A specific SMIs that prevent or reduce cell-cell interactions between B cell and DC/MΦ and alter the pathway of Ag processing and downstream B and T cell immunity. Importantly, by effectively reducing B cell to DC/MΦ Ag transfer, these SMIs can decrease overall T cell proliferation. We propose that these novel, SR-A specific SMIs will be effective in modulating Ag trafficking and reducing the induction of autoimmunity.
EXPERIMENTAL PROCEDURES
tm1Csk /J (SR-A -/-), C57Bl/6, B10.Br, Balb/c and MRL/MpJ-Fas lpr /2J (MRL) mice were obtained from the Jackson Laboratory. MRL mice were crossed to the SR-A -/-mice for greater than ten generations. Transgenic mice, expressing a surface membrane-restricted IgM gene (mIgM, also referred to as anti-NP), VH186.2, which partly encodes specificity for NP, were developed as described previously (18) . B10.Br AND Tg mice, expressing a PCC, MHC class II-restricted TCR were provided by Dr. Joseph Craft, Yale University. All animals were maintained in pathogen-free facilities at the Yale Animal Resources Center. Animal studies have been approved by Yale University Institutional Animal Care and Use Committee.
High throughput ELISA screening of small molecule inhibitors of SR-A
Recombinant human SR-A (rhSR-A; R&D Systems 2708-MS) was plated at 1µg/mL in 50mM carbonate buffer, pH9.6, (Sigma C30411) overnight at 4°C in high-binding 384-well plates (NUNC MaxiSorp 460518). Plates were washed three times then blocked with TBS/5% powdered milk/0.02% NaN 3 for 1hr at RT. Plates were washed four times and either DMSO or SMI (in DMSO) was added to plate at 10µM concentration for 1hr at RT. SMI libraries included the Microsource GenPlus library (960 compounds), the NIH Clinical Collection (445 compounds), and the Microsource Natural Compounds library (800 compounds). AcLDL-Biotin (Kalen Pharmaceuticals C7502), a natural ligand of SR-A, at 0.016ug/mL or Goat Anti-Macrophage Scavenger Receptor Type1 Polyclonal Antibody (Millipore AB5486; added at 1:20,000) overnight at 4°C. Plates were then washed four times, and either Extravidin-Alkaline Phosphatase (Sigma E2636) at 0.5µg/mL or donkey anti-goat-AlkPhos 1:500 (Sigma A4187) was used to detect AcLDL or the SR-A antibody, respectively. Plates were washed four times and fluorescein diphosphate (AnaSpec 85300) in buffer (50mM TrisHCl pH9.0/10mM MgCl 2 /10mM glycine) was added to wells at a 10µM concentration, and fluorescein product was detected.
In vitro Ag transfer from B cells to MΦs

2X10
6 human THP-1 cells were incubated with 10µM PMA for 24hrs. Human Burkitt's lymphoma cells (BJAB; gift provided by Dr. Charlie Benson, Georgia State University) were blocked with human FcR block (Miltenyi) and then treated with 10µg/mL F(ab')2 antihumanIgG-AF488 antibody (Invitrogen), as a model BCR-binding Ag, for 45min as described previously (8) . Cells were then washed extensively and added to the THP-1 MΦs in the presence of 50µM SMI or DMSO. 12hrs later, cells were trypsinized, stained for CD11b and CD19 and analyzed by flow cytometry (BD FACS Calibur). CD11b+ and CD19-cells were quantified for AF488-labeled Ag. 
In vivo Ag transfer from B cells to MΦs
Confocal microscopy and Ag quantification
PECs from MRL SR-A -/-and MRL+/+ mice were plated in 35mm glass bottom imaging chambers (MatTek ) at 6X10 6 cells per chamber and stained with 5µM CellTracker Orange CMRA (Invitrogen C34551). The adherent PECs were then treated with 20µM DMSO or SMI. Anti-NPspecific B cells were stained with 5µM CellTrace Far Red DDAO-SE (Invitrogen C34553) and treated with 10µg/mL NP-PCC-AF488. These cells were then washed extensively and added to the adherent PECs. Using a 40X objective, images of ten random fields in each chamber were acquired using the same imaging parameters. Biacore binding assay 500µg/mL rhSR-A was amine-coupled to CM5 dextran/gold-coated sensor chips (GE Healthcare BR-1005-30) using an amine-coupling kit (GE Healthcare BR-1000-50) for experiments performed on a Biacore T100 surface Plasmon resonance (SPR) system. Different concentrations of protein were bound to the chip depending on the number of protein injections, and bound rhSR-A was quantified prior to each experiment. DMSO or SMI (20µM) in HBS-P+ buffer (GE Healthcare BR-1006-71) was injected over the Biacore chip at a flow rate of 100µl/min to measure binding to coated rhSR-A. Human BJAB cells 2X10 6 cells/mL were washed two times, resuspended in buffer, and injected over the chip at a flow rate of 30µl/min. B cell binding to plated rhSR-A was detected and quantified. . 72hrs later, mice were euthanized and subjected to peritoneal lavage. The isolate was stained for CD4+ cells and analyzed by flow cytometry to quantify CFSE T cell proliferation.
In vivo T cell proliferation assay
RESULTS
SR-A is required for Ag transfer between B cells and MΦs/DCs.
Based on prior studies from our lab, mice genetically deficient of SR-A were evaluated for interactions between B cells and MΦs. PECs from wild type MRL+/+ and MRL SR-A -/-mice were incubated with Ag-pulsed transgenic anti-NPspecific B cells. Over time, MRL+/+ PECs broadly acquired fluorescent Ag from the Agpresenting B cells as assessed by flow cytometry and by confocal microscopy. The MRL SR-A -/-cells acquired significantly lower levels of Ag compared to the MRL+/+ cells (Fig. 1A) .
We next tested a specific antibody for SR-A that is able to block or inhibit receptor activity in order to evaluate the role of SR-A in Ag transfer in human cells. Human THP-1 cells were activated with PMA to an adherent state and then incubated with anti-SR-A antibody. Ag pulsed human BJAB cells were then added to the THP-1 cells. Similar to the SR-A deficient mice, inhibiting SR-A receptor activity reduced fluorescent Ag transfer compared to untreated THP-1 cells (Fig. 1B) . Therefore, we were able to utilize two separate systems to evaluate SR-A-mediated Ag transfer in SR-A positive or deficient mice and in human cells treated or untreated with anti-SR-A blocking antibody.
It is documented that SR-A mediates scavenging and clearance of a variety of extracellular ligands. This particular biological function might also be related to autoimmune disease development as apoptotic cells are a potential source of auto-Ags. One important natural ligand that SR-A binds and uptakes is AcLDL. We tested AcLDL in the human cell line Ag transfer system and determined that AcLDL does not inhibit Ag transfer (data not shown). Further, competition ELISAs revealed that AcLDL and the anti-SR-A antibody interact with recombinant human SR-A uniquely and with high avidity (data not shown). Therefore, it is unclear as to whether there is overlap in ligand uptake and Ag transfer functions or whether the anti-SR-A and AcLDL ligands might affect these SR-A functions separately.
A high throughput screening assay identified several SR-A specific SMIs.
We next sought to identify novel inhibitors of SR-A ligands in order to modulate SR-A biological activities and ultimately evaluate SR-A in the context of autoimmune disease. The inhibitor libraries consisted of three sets of biologically active compounds. Anti-SR-A antibody and AcLDL were defined as ligands with 100% binding to recombinant SR-A. We then assayed for inhibition of binding of these ligands following SMI treatment. These screens yielded 25 positive inhibitors, which ranged in inhibition for a low of ~30% to a high of ~90% (Sennoside B -87.5% inhibition of AcLDL; Bithionol -84.3% inhibition of AcLDL; Tannic Acid -76.4% inhibition of anti-SR-A) (Fig. 2) .
Positive candidates were further evaluated in a dose-dependent response screen. 13 compounds demonstrated measurable dose-dependent activity in anti-SR-A inhibition, AcLDL inhibition or in inhibiting both ligands. Several compounds exhibited low IC50 values (Table 1) . We next moved forward in analyzing the 13 compounds in biological assays.
SMIs can reduce SR-A mediated Ag transfer in human cells.
The SR-A specific compounds identified were tested in an in vitro live-cell assay for their ability to prevent Ag transfer. THP-1 cell line monocytes were PMA-activated to an adherent MΦ state. These cells were then treated with SMI, a corresponding volume of DMSO, anti-SR-A blocking antibody for positive inhibition control, or a non-specific antibody (negative inhibition control). Human BJAB cells were treated with Ag, washed extensively, and added to the adherent THP-1 MΦs. 12hrs later, cells were stained for either CD19 (to distinguish B cells) or CD11b (to distinguish MΦs) and analyzed by flow cytometry. Six SMIs were able to block fluorescent Ag transfer from B cells to MΦs significantly compared to control treatments (Fig. 3A) .
SMIs can reduce SR-A mediated Ag transfer in vivo in mice.
We then tested the efficacy of the SMI function in blocking Ag transfer in vivo. C57Bl/6 mice were primed with thioglycollate to induce an accumulation of PECs to the peritoneal cavity. A SR-A deficient mouse was also used as a control. Mice were IP injected with non-toxic doses of SMIs, and 2hrs later, Ag-pulsed anti-NP specific B cells (non-haplotype compatible with C57Bl/6 T cells, as described in methods) were IP injected. Five of the compounds were able to significantly inhibit Ag transfer to either MΦs, DCs or both cell types. Two of the compounds, tannic acid and sennoside B, were as effective at inhibiting Ag transfer to both MΦs and DCs as the SR-A deficient mouse (Fig. 3B) . These data also suggest that SMIs could potentially be used to modulate Ag transfer to different cell types.
A subset of SR-A positive cells can accumulate Ag over time.
PECs from either an MRL+/+ mouse or an MRL SR-A deficient mouse were plated in liveimaging chambers and treated with a cell tracker stain. Anti-NP B cells treated with NP-PCC-AF488 Ag were then added to the PECs, and the chambers were imaged periodically for 16hrs. Over time, a greater number of total cells expressing SR-A accumulated some Ag, but interestingly, a subset of these cells accumulated significant amounts of Ag compared to SR-A deficient cells (Fig. 4A-D) . The two most effective SMIs from the in vivo mouse Ag transfer experiments were evaluated to determine if they could reduce Ag accumulation in cells similarly to what is observed in SR-A deficient cells. MRL+/+ PECs were plated and treated with tannic acid or sennoside B. Ag-treated B cells were then added to the PECs, and the cell chambers were imaged at different time points. SR-A deficient cells were also plated and monitored over time. Images from untreated control, SMI-treated, and SR-A deficient cells were then analyzed for Ag positive fluorescent signal (AF488), reflecting Ag acquired from B cells. Cells were categorized into four groups based on fluorescence intensity (Fig. 5A) . Clearly, in the untreated control cells, a subpopulation of cells accumulated significant amounts of Ag compared to the SR-A -/-or SMItreated cells. The SMIs effectively prevented cells from accumulating or loading Ag in a manner similar to the SR-A deficient cells.
To determine if Ag accumulation of cells in a population subset was the result of particular cell type (i.e. DCs), we tested the THP-1 homogenous human monocyte cell line. PMA-activated human THP-1 cells were treated with sennoside B or tannic acid and imaged periodically. Again, rather than a reduction in the total number of cells receiving Ag, the inhibitors prevented more cells from receiving high levels of Ag. Specifically, in an untreated condition, many cells accumulate excess Ag, and the SMIs decrease this population of cells (Fig. 5B ). Observing this phenotype in both heterogenous primary mouse PECs and homogenous human cell lines suggests that there are not differences in the SR-A activity/function in the cell subsets acquiring Ag from B cells.
Sennoside B can reduce B cell capturing by SR-A.
One mechanism that could explain the observation that SR-A positive cells accumulate/load Ag compared to SR-A -/-cells is that an SR-A positive cell is more prone to stochastically interact with a B cell to form a stable cell-cell interaction conducive to Ag transfer. This stable interaction could enable or permit the Ag-loading observation to occur more frequently. Therefore, we next measured how effective the SMIs are at preventing MΦ and B cell interactions by Biacore SPR analysis. Sennoside B was the most specific in a dosedependent binding to rhSR-A. Further (Fig. 6 ).
Decreasing Ag transfer or accumulation with SMI treatment reduces T cell proliferation in vitro and in vivo.
Since sennoside B was effective at reducing Ag transfer and Ag loading in both mouse and human cells ex vivo and in mice in vivo, we wanted to determine if this effect translated to a reduction in T cell proliferation. Mouse PECs were plated and treated with SMIs. Anti-NP Agtreated B cells were then added to the PECs along with AND T cells (haplotype mismatch between these B and T cells as described in methods). This approach ensured that any T cell proliferation observed reflected Ag transfer only from MΦ/DC to T cell and not from B cell to T cell. Sennoside B was effective at reducing T cell proliferation in vitro (data not shown).
We next examined in vivo T cell proliferation in mice. IP thioglycollate injections were administered 48hrs in advance. Following SMI treatment, Ag-treated anti-NP B cells and CFSElabeled AND T cells were injected IP. 72hrs later, harvested peritoneal cells were stained for CD4 and analyzed by flow cytometry. Significant reductions in T cell proliferation were observed when mice were treated with sennoside B compared to DMSO-treated control mice (Fig. 7) .
DISCUSSION
In this study, we identified several novel and specific inhibitors of SR-A. Our initial HTS generated candidate compounds effective at blocking strong avidity ligands to SR-A. These molecules were then tested in dose-dependent titrations in a solid-state ELISA format to determine IC50 values. Specific SMIs were further tested in multiple biological systems for efficacy. Biological effectiveness in reducing Ag transfer between B cells and DC/MΦ ex vivo in both human and mouse cells and in vivo in mice provided compelling evidence that the SMIs selected were active and specific for SR-A. The ability of sennoside B to reduce T cell proliferation indicates that this SMI is effective in modulating an entire immunological pathway and may prove beneficial in quelling a systemic autoimmune response.
Interestingly, the most promising SMIs identified, tannic acid and sennoside B, were previously reported to have biological activity in autoimmune disease, cancer, and atherosclerosis. Administration of tannic acid to mice, for example, has been demonstrated to suppress inflammation and joint damage in rheumatoid arthritis (19) . Another study in mice demonstrated that tannic acid not only possesses its own scavenging activity of free radicals, but it also directly acts upon and reduces negative effects of the cytochrome p450 pathway implicated in DNA mutagenesis and cancer (20). Importantly, tannic acid was also recently used in several human clinical studies, and it was demonstrated to reduce the ability of E. coli to adhere in the urinary tract thereby reducing infection (21, 22) .
Sennoside B is a natural compound that is currently used in humans for gastrointestinal complications. Specifically, this compound can function as a laxative, and it is sometimes used acutely prior to colonoscopy. However, it has also been demonstrated to have anti-inflammatory or immuno-modulatory effects which include reducing paw oedema in rats and decreasing spleen size in animal models (23, 24) . Bacterial colonization of the gut has been illustrated to alter the course of Type I diabetes and rheumatoid arthritis autoimmunity in both humans and animal models (25, 26) .
Sennoside B demonstrated the highest degree of specificity for SR-A in the sensitive Biacore SPR binding assay, and it was also effective at reducing B cell interactions with rhSR-A in the SPR system. Understanding how sennoside B affects the mucosal intestinal immune system could provide important clues into the SR-A pathway and the biological implications of this drug as an immuno-modulatory compound. In addition, sennoside B has been demonstrated to inhibit PDGF receptor signaling and cell proliferation induced by PDGF-BB in human osteosarcoma cells (27) .
The structures of both sennoside B and tannic acid exhibit polyanionic characteristics, an attribute common amongst SR-A ligands. Sennoside B not only demonstrated specificity for SR-A, but it is also biologically active in reducing Ag transfer in mouse and human systems. However, based on the complexity and diversity of SR-A function, it is possible that some of the other SMIs with less pronounced effects are biologically active in unique ways. For example, an important recent study reveals a role for SR-A in counterbalancing TLR cell activation to essentially suppress a MΦ/DC-mediated immune response (28) . This suppressive activity, which likely involves endocytic regulation of SR-A, could be favorable in protecting against autoimmunity.
A finding in our study indicates that a population of SR-A positive cells can accumulate Ag in much greater quantities over time compared to SR-A -/-cells or SMI-treated cells. Based on the complex nature of SR-A it is possible that this SMI effect can occur in multiple ways. Our results demonstrate that prolonged, stable interaction between Ag-presenting B cells and MΦs or DCs allows single cells to acquire significant levels of transferred antigen.
Herein, we report the identification of several small molecules that inhibit SRA biologic activity by altering Ag processing pathways and subsequent B and T cell responses, including a reduction in T cell proliferation. Our findings have broad implications in understanding the immunological events leading to a focused immune response directed toward a select group of Ags, whether foreign or self in lupus autoimmunity. Examining these small molecules in spontaneous models of SLE to determine effects on the induction of SLE disease onset will be the next step in characterizing these SMIs for SR-A in the context of autoimmunity. 
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